David R. Liu

NeoadjuvantDoxorubicin / CyclophosphamideFollowedby IxabepiloneorPaclitaxel inEarly StageBreastCancerandEvaluationof III-TubulinExpressionasaPredictiveMarker

Cynthia, C. Horak, F. Symmans, 2013 .

A randomized, phase II, three-arm study of two schedules of ixabepilone or paclitaxel plus bevacizumab as first-line therapy for metastatic breast cancer

D. Amadori, H. Rugo, M. Campone, 2013, Breast Cancer Research and Treatment.

Biomarker Analysis of Neoadjuvant Doxorubicin/Cyclophosphamide Followed by Ixabepilone or Paclitaxel in Early-Stage Breast Cancer

L. Pusztai, C. Horak, O. Trifan, 2013, Clinical Cancer Research.

Neoadjuvant doxorubicin/cyclophosphamide followed by ixabepilone or paclitaxel in early stage breast cancer and evaluation of βIII-tubulin expression as a predictive marker.

Cynthia, P. Fasching, L. Pusztai, 2013, The oncologist.

Predictive Biomarkers and Personalized Medicine Biomarker Analysis of Neoadjuvant Doxorubicin / Cyclophosphamide Followed by Ixabepilone or Paclitaxel in Early-Stage Breast Cancer

L. Pusztai, C. Horak, O. Trifan, 2013 .